CIBC Private Wealth Group
TSHA icon

CIBC Private Wealth Group’s Taysha Gene Therapies TSHA Stock Holding History

CIBC Private Wealth Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,833
Closed -$7.72K – 3312
2025
Q1 		$7.72K Hold
6,833
– – ﹤0.01% 2318
2024
Q4 		$13.2K Hold
6,833
– – ﹤0.01% 2182
2024
Q3 		$13.7K Buy
+6,833
New +$15K ﹤0.01% 2310

Other funds holding TSHA

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIBC Private Wealth Group's TSHA Position: Q2 2025 in Review

CIBC Private Wealth Group sold out of Taysha Gene Therapies (TSHA) in Q2 2025, closing a stake of 6,833 shares — an estimated $7.72K sold.

CIBC Private Wealth Group first reported a position in TSHA in Q3 2024 and held it in 3 quarters. The position peaked at $13.7K in Q3 2024. 150 funds tracked by Wall St. Rank hold TSHA as of Q2 2025.

  • CIBC Private Wealth Group reported no remaining Taysha Gene Therapies position as of Q2 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 6,833 Taysha Gene Therapies shares in Q2 2025, an estimated $7.72K.
  • CIBC Private Wealth Group first reported a position in Taysha Gene Therapies in Q3 2024 and held it in 3 quarters.
  • CIBC Private Wealth Group's Taysha Gene Therapies position peaked at $13.7K in Q3 2024.
  • 150 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2025.

Based on CIBC Private Wealth Group's 13F filing for Q2 2025, filed 12 Aug 2025.